Literature DB >> 11564644

A xanthine-based KMUP-1 with cyclic GMP enhancing and K(+) channels opening activities in rat aortic smooth muscle.

B N Wu1, R J Lin, C Y Lin, K P Shen, L C Chiang, I J Chen.   

Abstract

1. KMUP-1 (1, 3, 5 mg kg(-1), i.v.), a xanthine derivative, produced dose-dependent sustained hypotensive and short-acting bradycardiac effects in anaesthetized rats. This hypotensive effect was inhibited by pretreatment with glibenclamide (5 mg kg(-1), i.v.). 2. In endothelium-intact or denuded aortic rings preconstricted with phenylephrine, KMUP-1 caused a concentration-dependent relaxation. This relaxation was reduced by endothelium removal, the presence of NOS inhibitor L-NAME (100 microM) and sGC inhibitors methylene blue (10 microM) and ODQ (1 microM). 3. The vasorelaxant effects of KMUP-1 was attenuated by pretreatment with various K(+) channel blockers TEA (10 mM), glibenclamide (1 microM), 4-AP (100 microM), apamin (1 microM) and charybdotoxin (ChTX, 0.1 microM). 4. Increased extracellular potassium levels (30 - 80 mM) caused a concentration-related reduction of KMUP-1-induced vasorelaxations. Preincubation with KMUP-1 (1, 10, 100 nM) increased the ACh-induced maximal vasorelaxations mediated by endogenous NO release, and enhanced the potency of exogenous NO-donor SNP. 5. The vasorelaxant responses of KMUP-1 (0.01, 0.05, 0.1 microM) together with a PDE inhibitor IBMX (0.5 microM) had an additive action. Additionally, KMUP-1 (100 microM) affected cyclic GMP metabolism since it inhibited the activity of PDE in human platelets. 6. KMUP-1 induced a dose-related increase in intracellular cyclic GMP levels in rat A10 vascular smooth muscle (VSM) cells, but not cyclic AMP. The increase in cyclic GMP content of KMUP-1 (0.1 - 100 microM) was almost completely abolished in the presence of methylene blue (10 microM), ODQ (10 microM), and L-NAME (100 microM). 7. In conclusion, these results indicate that KMUP-1 possesses the following merits: (1) stimulation of NO/sGC/cyclic GMP pathway and subsequent elevation of cyclic GMP, (2) K(+) channels opening, and (3) inhibition of PDE or cyclic GMP breakdown. Increased cyclic GMP display a prominent role in KMUP-1-induced VSM relaxations.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11564644      PMCID: PMC1572942          DOI: 10.1038/sj.bjp.0704231

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  27 in total

1.  Regulation of adenosine cyclic 3',5'-monophosphate and guanosine cyclic 3',5'-monophosphate levels and contractility in bovine tracheal smooth muscle.

Authors:  S Katsuki; F Murad
Journal:  Mol Pharmacol       Date:  1977-03       Impact factor: 4.436

2.  Ca2+ current is regulated by cyclic GMP-dependent protein kinase in mammalian cardiac myocytes.

Authors:  P F Méry; S M Lohmann; U Walter; R Fischmeister
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

Review 3.  Biosynthesis and metabolism of endothelium-derived nitric oxide.

Authors:  L J Ignarro
Journal:  Annu Rev Pharmacol Toxicol       Date:  1990       Impact factor: 13.820

4.  Nitric oxide activates guanylate cyclase and increases guanosine 3':5'-cyclic monophosphate levels in various tissue preparations.

Authors:  W P Arnold; C K Mittal; S Katsuki; F Murad
Journal:  Proc Natl Acad Sci U S A       Date:  1977-08       Impact factor: 11.205

5.  Release of nitric oxide from endothelial cells stimulated by YC-1, an activator of soluble guanylyl cyclase.

Authors:  P Wohlfart; T Malinski; H Ruetten; U Schindler; W Linz; K Schoenafinger; H Strobel; G Wiemer
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

6.  Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity.

Authors:  J Galle; U Zabel; U Hübner; A Hatzelmann; B Wagner; C Wanner; H H Schmidt
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

7.  Human blood platelet 3': 5'-cyclic nucleotide phosphodiesterase. Isolation of low-Km and high-Km phosphodiesterase.

Authors:  H Hidaka; T Asano
Journal:  Biochim Biophys Acta       Date:  1976-04-08

8.  An indirect influence of phenylephrine on the release of endothelium-derived vasodilators in rat small mesenteric artery.

Authors:  K A Dora; J M Hinton; S D Walker; C J Garland
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

9.  Activation of sulphonylurea-sensitive channels and the NO-cGMP pathway decreases the heart rate response to sympathetic nerve stimulation.

Authors:  R M Mohan; D J Paterson
Journal:  Cardiovasc Res       Date:  2000-07       Impact factor: 10.787

10.  Comparison of the effects of BRL 34915 and verapamil on electrical and mechanical activity in rat portal vein.

Authors:  T C Hamilton; S W Weir; A H Weston
Journal:  Br J Pharmacol       Date:  1986-05       Impact factor: 8.739

View more
  15 in total

1.  KMUP-1 relaxes rabbit corpus cavernosum smooth muscle in vitro and in vivo: involvement of cyclic GMP and K(+) channels.

Authors:  Rong-Jyh Lin; Bin-Nan Wu; Yi-Ching Lo; Kuo-Pyng Shen; Young-Tso Lin; Chun-Hsiung Huang; Ing-Jun Chen
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

2.  Actions of KMUP-1, a xanthine and piperazine derivative, on voltage-gated Na(+) and Ca(2+) -activated K(+) currents in GH3 pituitary tumour cells.

Authors:  Yi-Ching Lo; Yu-Ting Tseng; Chi-Ming Liu; Bin-Nan Wu; Sheng-Nan Wu
Journal:  Br J Pharmacol       Date:  2015-10-25       Impact factor: 8.739

3.  KMUP-1 activates BKCa channels in basilar artery myocytes via cyclic nucleotide-dependent protein kinases.

Authors:  Bin-Nan Wu; Hsiao-Fang Tu; Donald G Welsh; Ing-Jun Chen
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

4.  The xanthine derivative KMUP-1 inhibits models of pulmonary artery hypertension via increased NO and cGMP-dependent inhibition of RhoA/Rho kinase.

Authors:  Hui-Hsuan Chung; Zen-Kong Dai; Bin-Nan Wu; Jwu-Lai Yeh; Chee-Yin Chai; Koung-Shing Chu; Chung-Pin Liu; Ing-Jun Chen
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

5.  KMUP-3 attenuates ventricular remodelling after myocardial infarction through eNOS enhancement and restoration of MMP-9/TIMP-1 balance.

Authors:  Chung-Pin Liu; Jwu-Lai Yeh; Bin-Nan Wu; Chee-Yin Chai; Ing-Jun Chen; Wen-Ter Lai
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

6.  KMUP-1 attenuates isoprenaline-induced cardiac hypertrophy in rats through NO/cGMP/PKG and ERK1/2/calcineurin A pathways.

Authors:  Jwu-Lai Yeh; Jong-Hau Hsu; Ping-Ju Wu; Shu-Fen Liou; Chung-Pin Liu; Ing-Jun Chen; Bin-Nan Wu; Zen-Kong Dai; Jiunn-Ren Wu
Journal:  Br J Pharmacol       Date:  2010-02-02       Impact factor: 8.739

7.  KMUP-1, a xanthine derivative, induces relaxation of guinea-pig isolated trachea: the role of the epithelium, cyclic nucleotides and K+ channels.

Authors:  Bin-Nan Wu; Rong-Jyh Lin; Yi-Ching Lo; Kuo-Pyng Shen; Chao-Chuan Wang; Young-Tso Lin; Ing-Jun Chen
Journal:  Br J Pharmacol       Date:  2004-07-05       Impact factor: 8.739

8.  Activation of BKCa channels via cyclic AMP- and cyclic GMP-dependent protein kinases by eugenosedin-A in rat basilar artery myocytes.

Authors:  B-N Wu; C-F Chen; Y-R Hong; S-L Howng; Y-L Lin; I-J Chen
Journal:  Br J Pharmacol       Date:  2007-08-13       Impact factor: 8.739

9.  Direct activation of β-cell KATP channels with a novel xanthine derivative.

Authors:  Rene Raphemot; Daniel R Swale; Prasanna K Dadi; David A Jacobson; Paige Cooper; Andrew P Wojtovich; Sreedatta Banerjee; Colin G Nichols; Jerod S Denton
Journal:  Mol Pharmacol       Date:  2014-03-19       Impact factor: 4.436

10.  KMUP-1 suppresses RANKL-induced osteoclastogenesis and prevents ovariectomy-induced bone loss: roles of MAPKs, Akt, NF-κB and calcium/calcineurin/NFATc1 pathways.

Authors:  Shu-Fen Liou; Jong-Hau Hsu; I-Ling Lin; Mei-Ling Ho; Pei-Chuan Hsu; Li-Wen Chen; Ing-Jun Chen; Jwu-Lai Yeh
Journal:  PLoS One       Date:  2013-07-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.